The study was conducted in general compliance with the U.S. Food and Drug Administration and Good Laboratory Practice (GLP) regulations set forth in 21 CFP Part 58 modified in certain of the procedures. Kappa Laboratories, the venue of the test, has also been inspected and previously recognized by the U.S. Department of Agriculture. They are registered with the U.S. Food and Drug Administration and is an FDA Accepted Laboratory for Import Testing.
The test was carried out against known prevalent causes of fungal infections in people, such as Staphylococcus Aureus, Pseudomonas Aeruginosa, E.Coli, Candida Albicans, and Aspergillus Niger. Dr. Peter J. Kmieck led the team in carrying out the objective of the study, which was to evaluate the Time Kill Kinetics of antimicrobial activity of the EMUAID® and EMUAIDMAX® ointments against the aforementioned bacteria strains.
The reagents used included phosphate buffer stock and buffer dilution water. Apparatus used included glassware such as beakers, disposable petri dishes, pipettes, and a magnetic stir plate. Culture media included trypticase soy broth and agar, which was also used for the subculture media in addition to FCD broth.